FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer
NCT00323011
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Patients with histologically or cytologically confirmed metastatic or recurrent colorectal tumors with no previous treatment for advanced disease.
- Age > 18 years (as no dosing or toxicity data are currently available on the use of 5-FU/CPT11 + bevacizumab + dalteparin in patients <18 years of age).
- SWOG performance status 0-1.
- Patients must have adequate organ and marrow function as defined below, with tests performed no more than seven days prior to the first study drug administration:leukocytes >3.0, absolute neutrophil count >1,500/ml,platelets > 100 X 109 L ,total bilirubin < upper normal institutional limits,AST(SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal ( or < 5x the upper normal institutional limits in the case of liver metastases,alkaline phosphatase < 2.5 X institutional upper limit of normal ( or < 5x the upper normal institutional limits in the case of liver metastases or < 10x the upper normal institutional limits in the case of bone disease, Serum creatinine < 1.6 mg/dL OR Calculated creatinine clearance > 40 mL/min/1.73 m2, PT, PTT, within normal range, Urine protein/creatinine ratio < 1.0
- At least one measurable lesion according to the RECIST criteria which has not been irradiated (i.e. newly arising lesions in previously irradiated areas are accepted). Ascites, pleural effusion, and bone metastases are not considered measurable. Minimum indicator lesion size: > 10 mm measured by spiral CT or >20mm measured by conventional techniques.
- The effects of chemotherapy on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation and 30 days from the date of the last study drug administration (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential). Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- Ability to understand and willingness to sign a written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.
- Have a negative serum pregnancy test within 7 days prior to initiation of chemotherapy (female patients of childbearing potential).
- Life expectancy of at least 12 weeks.
- Fully recovered from any surgical procedure
- Lactating woman unwilling to stop breast feeding for the duration of study
participation and 30 days from the date of the last study drug administration
- History of allergy to any of the chemotherapeutics or antiemetics appropriate for
administration in conjunction with protocol-directed chemotherapy.
- Prior unanticipated severe reaction to fluoropyrimidine therapy, known
hypersensitivity to 5-fluorouracil, or known DPD deficiency.
- Serious, uncontrolled, intercurrent infection(s) or illnesses including, but not
limited to ongoing or active infection, symptomatic congestive heart failure, or
unstable angina pectoris, or cardiac arrhythmia.
- Treatment for other carcinomas within the last five years, except cured non-melanoma
skin and treated in-situ cervical cancer.
- Current, recent (within 4 weeks of first infusion on this study) or planned
participation in an investigational drug study.
- Patients with documented DIC (disseminated intravascular coagulation).
- Patients with a previous history of a bleeding diathesis or significant bleeding
episode such as gastrointestinal bleeding or a CNS hemorrhage.
- Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic
coronary artery disease and cardiac arrhythmias not well controlled with medication)
within the last 12 months.
- Presence of central nervous system or brain mets.
- Major surgery, open biopsy, or significant traumatic injury within 28 days prior to
Day 1, or anticipation of need for major surgical procedure during the course of the
study.
- Unwillingness to participate or inability to comply with the protocol for the duration
of the study.
- Minor surgical procedures, fine needle aspirations or core biopsies within 7 days
prior to Day 1.
- Blood pressure > 150/100 mmHg.
- Unstable angina.
- New York Heart Association (NYHA) Grade II or greater congestive heart failure.
- History of myocardial infarction or stroke within 6 months.
- Clinically significant peripheral vascular disease.
- Evidence of bleeding diathesis or coagulopathy.
- History of abdominal fistula, gastrointestinal perforation or intrabdominal abscess
within 28 days prior to Day 0.
- Serious, non-healing wound, ulcer or bone fracture.
- Carcinoma of any histology in close proximity to a major vessel, lung cavitation or
history of hemoptysis.
- Completion of previous chemotherapy regimen < four weeks prior to the start of study
treatment (within six weeks of study treatment for mitomycin C and nitrosureas), or
with related toxicities unresolved prior to the start of study treatment.
- Patients who are taking anti coagulation therapy such as coumadin or low molecular
weight Heparin.
- Patients who have an allergy against heparin.
- Medical, social or psychological factors which would interfere with consent and follow
up.
- Known defective hemostasis, e.g. thrombocytopenia.
- Patients receiving Hormone Replacement Therapy.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- London,
- Chicago, Illinois
- Galesburg, Illinois
- Bloomington, Indiana
- Evansville, Indiana
- Indianapolis, Indiana
- Indianapolis, Indiana
- Indianapolis, Indiana
- Indianapolis, Indiana
- Lafayette, Indiana
- Lafayette, Indiana
- Munster, Indiana
- New Albany, Indiana
- South Bend, Indiana
- St. Louis, Missouri
- Jonesboro, Arkansas
- Fort Myers, Florida
- Pensacola, Florida
- Saint Petersburg, Florida
- Gainesville, Georgia
- Newburgh, Indiana
- Terre Haute, Indiana
- Grand Rapids, Michigan
- Omaha, Nebraska
- Summit, New Jersey
- Nashville, Tennessee
- Dallas, Texas
- Los Angeles, California
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer | |||
Official Title ICMJE | A Randomized Pilot Study of the Activation of the Hemostatic Pathway by FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer | |||
Brief Summary | This study is for people with colorectal cancer, who have tumors that cannot be completely removed by surgery. Blood clots are a problem in patients with cancer. Blood clots are also a problem in patients receiving cancer drugs. Studies have shown that up to 17% of patients receiving cancer drugs experienced blood-clotting problems. One purpose of this study is to find if the drug combination of irinotecan, 5-fluorouracil (5-FU), bevacizumab and leucovorin (LV) affect blood-clotting factors. A second purpose of this study is to find out what effects the drug dalteparin has on clotting factors in the blood in patients receiving the drug combination of irinotecan, 5-FU, bevacizumab and LV. It is hoped that adding dalteparin to chemotherapy may benefit patients with colorectal cancer by preventing blood clots | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Factorial Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Colorectal Cancer | |||
Intervention ICMJE | Drug: Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab | |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Terminated | |||
Actual Enrollment ICMJE | 5 | |||
Original Enrollment ICMJE | 30 | |||
Actual Study Completion Date ICMJE | November 2007 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00323011 | |||
Other Study ID Numbers ICMJE | 3C-05-2 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Syma Iqbal, MD, University of Southern California | |||
Study Sponsor ICMJE | University of Southern California | |||
Collaborators ICMJE | Pfizer | |||
Investigators ICMJE |
| |||
PRS Account | University of Southern California | |||
Verification Date | May 2014 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |